期刊文献+

二肽基肽酶4抑制剂心血管保护作用的研究进展 被引量:8

Recent Progress in Cardiovascular Protective Effects of Dipeptidyl Peptidase 4 Inhibitors
下载PDF
导出
摘要 二肽基肽酶4(DPP-4)抑制剂是一类新型的糖尿病治疗药物,近年来研究显示DPP-4抑制剂对心血管系统有重要的保护作用,引起广大心脏病学者的极大兴趣。DPP-4抑制剂具有抗炎、抗动脉粥样硬化、改善心肌代谢等作用,可减少心肌梗死面积,减少缺血再灌注损伤,稳定心肌缺血时电生理状态,改善心室重构,并动员干细胞至心血管损伤处,促进组织修复。现将DPP-4抑制剂心血管保护作用的研究进展做一综述。 Dipeptidyl peptidase 4 ( DPP-4 ) inhibitors are a new class of drugs for the treatment of diabetes. Many studies have shown that DPP-4 inhibitor has an important protective effect on the cardiovascular system. DPP-4 inhibitor can suppress inflammation, atherosclerosis and improve myocardial metabolism. It results in smaller infarct size, reduces ischemia/reperfusion injury, stabilizes the cardiac elec- trophysiological state during myocardial ischemia and improves ventricular remodeling. In addition, DPP-4 inhibitor can mobilize stem cells to the site of cardiovascular injury, and promote tissue repair. This article reviews recent progress in researching the cardiovascular protective effects of DPP-4 inhibitors.
出处 《心血管病学进展》 CAS 2012年第5期593-596,共4页 Advances in Cardiovascular Diseases
关键词 DPP-4抑制剂 心血管保护 dipeptidyl-peptidase 4 inhibitor cardiovascular protection
  • 相关文献

参考文献28

  • 1Ta NN, Li Y, Schuyler CA, et al. Dpp-t (CD26) inhibitor aloghptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes [ J ]. Atherosclerosis, 2010, 213 (2) : 429435.
  • 2Takasawa W, Ohnuma K, Hatano R, et ah Inhibit on of dipeptidyl peptidase 4 regulates mierovascular endothelial growth induced by inflammatory cytokines [ J]. Bioehem Biophys Res Commun, 2010,401 (1) :7-12.
  • 3Ferreira L, Teixeira-De-Lemos E, Pinto F, et al. Effects of sitag]iptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)[J]. Mediators Inflamm, 2010, 2010:592760.
  • 4Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 in- hibition reduces atheroselerosis and inflammation via effects on monoeyte recruit- ment and ehemotaxis[J]. Circulation, 2011,124(21) :2338-2349.
  • 5Huisamen B, Genis A, Marais E, et al. Pre-treatment with a DPP-4 inhihitor is infarct sparing in hearts from obese, pre-diabetic rats [ J ]. Cardiovasc Drugs T- her, 2011,25( 1 ) :13-20.
  • 6Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is par- tially dependent on PKA[J]. Am J Physiol Heart Circ Physiol, 2010, 298(5) : H1454-H1465.
  • 7Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhi- bition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardi- al infarction in mice[J]. Diabetes, 2010, 59(4) :1063-1073.
  • 8Chinda K, Palee S, Surinkaew S, et al. Cardioprotective effect of dipeptidy| peptidase-4 inhibitor during ischemia-reperfusinn injury [ J ]. Int J Cardiol, 2012, [ Epub ahead of print].
  • 9Yin M, Sillje HH, Meissner M, et al. Early and late effects of the DPP4 inhib- itor vildagliptin in a rat model of post-myocardial infarction heart ihilure [ J ]. Cardiovasc Diabetol, 2011,10 ( 1 ) : 85.
  • 10Sokos GG, Nikolaidis LA, Mankad S, el al. Glacagon-like peptide-I infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure[J]. J Card Fail, 2006, 12(9) : 694-699.

同被引文献80

  • 1韩慧萍,杨一,杨文.老年心肌梗死的早期预警指标[J].中国老年学杂志,2014,34(12):3514-3515. 被引量:6
  • 2Minoru Itou,Takumi Kawaguchi,Eitaro Taniguchi,Michio Sata.Dipeptidyl peptidase-4: A key player in chronic liver disease[J].World Journal of Gastroenterology,2013,19(15):2298-2306. 被引量:25
  • 3仇万山,陈亦江.线粒体结构、功能和常用研究方法[J].国际麻醉学与复苏杂志,2007,28(3):282-285. 被引量:22
  • 4Monami M,Iacomelli I,Marchionni N. Dipeptydil peptidase-4 inhibitors in type 2 diabetes:a meta-analysis of randomized clinical trials[J].{H}Nutrition Metabolism and Cardiovascular Diseases,2010,(04):224-235.
  • 5Drucker D J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes:preclinical biology and mechanisms of action[J].{H}DIABETES CARE,2007,(06):1335-1343.
  • 6Dang D T,Chun S Y,Burkitt K. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition[J].{H}CANCER RESEARCH,2008,(06):1872-1880.
  • 7Anagnostis P,Athyros V G,Adamidou F. Glucagonlike peptide-1-based therapies and cardiovascular disease:looking beyond glycaemic control[J].{H}Diabetes Obesity & Metabolism,2011,(04):302-312.
  • 8Erdogdu O,Nathanson D,Sjoholm A. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS,PKA-and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J].{H}Molecular and Cellular Endocrinology,2010,(1-2):26-35.
  • 9Goto H,Nomiyama T,Mita T. Exendin-4,a glucagon-like peptide-1 receptor agonist,reduces intimal thickening after vascular injury[J].{H}Biochemical and Biophysical Research Communications,2011,(01):79-84.
  • 10Ban K,Kim K H,Cho C K. Glucagon-like peptide (GLP)-1 (9-36)amide-mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor[J].{H}ENDOCRINOLOGY,2010,(04):1520-1531.

引证文献8

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部